Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Assets (2016 - 2025)

Haemonetics (HAE) has 16 years of Assets data on record, last reported at $2.5 billion in Q4 2025.

  • For Q4 2025, Assets fell 1.6% year-over-year to $2.5 billion; the TTM value through Dec 2025 reached $2.5 billion, down 1.6%, while the annual FY2025 figure was $2.5 billion, 11.63% up from the prior year.
  • Assets reached $2.5 billion in Q4 2025 per HAE's latest filing, up from $2.4 billion in the prior quarter.
  • Across five years, Assets topped out at $2.5 billion in Q2 2024 and bottomed at $1.8 billion in Q3 2021.
  • Average Assets over 5 years is $2.1 billion, with a median of $2.0 billion recorded in 2023.
  • Peak YoY movement for Assets: skyrocketed 43.63% in 2021, then dropped 3.29% in 2025.
  • A 5-year view of Assets shows it stood at $1.8 billion in 2021, then rose by 4.25% to $1.9 billion in 2022, then increased by 17.16% to $2.2 billion in 2023, then rose by 15.04% to $2.5 billion in 2024, then decreased by 1.6% to $2.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $2.5 billion in Q4 2025, $2.4 billion in Q3 2025, and $2.5 billion in Q2 2025.